Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | TACR2 | P21452 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TST | Q16762 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172696 | 0.98 | ESR1 (0.63) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL1171632 | 0.98 | ESR1 (0.63) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL9143112 | 0.98 | ESR1 (0.63) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL11557511 | 0.98 | ESR1 (0.63) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL1428981 | 0.93 | ESR1 (0.62) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL449737 | 0.87 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL2177163 | 0.87 | THRA (0.47) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL9673266 | 0.85 | THRA (0.50) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL9673289 | 0.85 | THRA (0.50) | ESR1ADRA2ASLC6A2ADORA3TACR2 | |
| SCHEMBL1447579 | 0.85 | ESR1 (0.77) | ESR1ADRA2ASLC6A2ADORA3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-0971709-B1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | PANETTA JILL ANN (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | PANETTA JILL ANN (US) | 2002-11-28 | — | — | US | disclosed |
| US-6472387-B1 | Methods of using compounds as neuro-protective agents | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6448396-B2 | 2-((3,5-DIALKYL-4-HYDROXYPHENYL-4-(2-(AMINOALKYLPHENOXY)ETHYL) OXAZOLES; ANTIISCHEMIC AGENTS; REPERFUSION INJURY OF PERIPHERAL ORGANS; FREE RADICAL ANTAGONISTS; PARKINSON'S AND ALZHEIMER'S DISESES; DOWN'S SYNDROME; AMYOTROPHIC LATERAL S. | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6423709-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYTROPHIC LATERAL SCLEROSIS OR CEREBRAL TRAUMA IN A MAMMAL | ELI LILLY AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY | 2001-10-04 | — | — | US | disclosed |
| WO-1999009979-A1 | METHOD FOR TREATING NEUROPATHIC PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009980-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0830709-A4 | ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS | MOLTECH CORP (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998015274-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0830709-A1 | ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS | Moltech Corporation (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996029753-A9 | ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS | — | 1997-01-16 | — | — | WO | disclosed |
| WO-1996029753-A1 | ELECTROLYTE MATERIALS CONTAINING HIGHLY DISSOCIATED METAL ION SALTS | MOLTECH CORPORATION (US) | 1996-09-26 | — | — | WO | disclosed |
| US-5538812-A | ELECTROLYTIC CELLS WITH POLYETHERSILOXANES WITH GROUPS OF TRIFLUOROMETHANESULFONYL | MOLTECH CORPORATION (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0301421-B1 | SULFUR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICINES | Roche Diagnostics GmbH (DE) | 1991-08-28 | — | — | EP | disclosed |
| EP-0301421-A2 | Sulfur compounds, process for their preparation and medicines | Roche Diagnostics GmbH (DE) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | NLN, PRDX5, TXN2 | ESR1 4584/4885ADRA2A 1182/4885SLC6A2 787/4885 |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | NLN, PRDX5, TXN2 | ESR1 4584/4885ADRA2A 1182/4885SLC6A2 787/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | ESR1 4778/4885ADRA2A 1646/4885SLC6A2 614/4885 |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | NLN, GAP43, TXN2 | ESR1 4778/4885ADRA2A 1646/4885SLC6A2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.